У нас вы можете посмотреть бесплатно EP 223: Live at JPM: Rewriting disease with genetic medicine with Michelle Werner & Mike Severino или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
This week on The Genetics Podcast, Patrick is joined for a special recording at the Flagship Pioneering studio during JPM 2026 by Michelle Werner, CEO of Alltrna, and Michael Severino, CEO of Tessera Therapeutics. They discuss the molecular mechanisms behind Alltrna’s engineered tRNA and Tessera’s gene-writing platforms, why 2026 marks a major inflection point as both programs enter the clinic, and considerations around trial design, patient needs, and delivering therapies at scale. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Michelle & Michael 01:29 Overview of Alltrna’s therapeutic approach to rare genetic diseases using engineered tRNAs 03:24 Overview of Tessera Therapeutics’ gene writing approach 04:59 Preclinical evidence supporting first-in-human testing of Alltrna’s lead candidate 08:07 Why Tessera’s preclinical models are predictive of clinical success 11:03 Key features that differentiate Tessera’s RNA-based gene writing 14:30 Advantages of using basket trials for engineered tRNAs 18:30 Clinical trial design and early efficacy signals for gene writing in alpha-1 antitrypsin deficiency 22:40 Genetic testing, patient identification, and patient advocacy in Alltrna trials 25:03 Differentiating Tessera’s gene writing approach for patients and investigators 27:28 Site readiness and expertise required for genetic medicine trials 29:29 Scaling Alltrna’s platform across mutations, tissues, and diseases 33:38 Expanding Tessera’s gene writing platform beyond alpha-1 antitrypsin deficiency 37:06 Perspectives on biotech funding, pharma partnerships, and rare disease investment 40:22 The data pharma looks for when partnering on novel genetic therapies 44:12 Emerging technologies Michelle and Michael are watching beyond their own platforms 48:47 Closing remarks Find out more: Alltrna (https://www.alltrna.com/) Tessera Therapeutics (https://www.tesseratherapeutics.com/) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_...